更昔洛韦联合胸腺肽治疗小儿巨细胞病毒感染疗效分析  

Efficacy Analysis of Ganciclovir combined Thymosin Treatment of Cytomegalovirus Infection in Children

作　　者：姜凤朝[1] 何依绮[1] 王文佳[1] 

机构地区：[1]广东省第二人民医院儿科,广东广州510317

出　　处：《中国医药指南》2011年第25期195-196,共2页Guide of China Medicine

摘　　要：目的探究更昔洛韦联合胸腺肽在HCMV感染的小儿患者治疗中的临床应用价值。方法采用前瞻性开放研究,共收集80例在我院就诊的人类巨细胞病毒(HCMV)小儿患者,分别进行更昔洛韦联合胸腺肽治疗和单用更昔洛韦治疗,经统计学分析比较两组治疗的总有效率和不良反应发生率。结果将二者总有效率和不良反应率采用SPSS18.0统计软件进行卡方检验后,差异均有统计学意义(P值均<0.05)。结论更昔洛韦与胸腺肽联合治疗小儿巨细胞病毒感染的疗效明显优于单用更昔洛韦治疗,且其不良反应明显低于后者,因此值得在临床上推广应用。Objective Explore ganciclovir combined with thymosin in the treatment of HCMV infection in pediatric patients with clinical value.Methods A prospective open study,collected 80 cases in our hospital＇s human cytomegalovirus（HCMV） in pediatric patients,respectively ganciclovir thymosin treatment and single treatment with ganciclovir,the statistical analysis and comparison of two the total efficiency of the treatment group and the incidence of adverse reactions.Results Both efficient and adverse reaction rates using statistical software SPSS18.0 chi-square test,the differences were statistically significant（P〈0.05）.Conclusion Thymosin combination therapy with ganciclovir of cytomegalovirus infection in children＇s significantly better than single treatment with ganciclovir,and their adverse reactions was significantly lower than the latter,so worthy of clinical application.

关 键 词：HCMV感染 更昔洛韦联合胸腺肽治疗 单用更昔洛韦治疗 

分 类 号：R512.5[医药卫生—内科学]